

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF ART UNIT: 1646
AZRIA, MOISE ET AL. EXAMINER: XIE, XIAOZHEN
INTERNATIONAL APPLICATION NO: PCT/EP2004/008210
FILED: JULY 22, 2004
U.S. APPLICATION NO: 10/565455
35 USC §371 DATE: APRIL 05, 2006
FOR: USE OF CALCITONIN IN OSTEOARTHRITIS

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT


Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936
(862) 778-9308
Date: 11/10/09

Respectfully submitted,



Leslie Fischer
Attorney for Applicant
Reg. No. 58,393